Files and links (1)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension
International journal of clinical practice (Esher), v 62(s160), pp 5-9
01 Jul 2008
PMID: 18638170
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Intravenous prostanoids are the backbone of therapy for advanced pulmonary arterial hypertension (PAH) and have improved long-term outcome and quality of life. Currently, two prostanoids are approved by the US Food and Drug administration for parenteral administration: epoprostenol (Flolan) and treprostinil (Remodulin). Chronic intravenous therapy presents considerable challenges for patients and caregivers who must learn sterile preparation of the medication, operation of the pump, and care of the central venous catheter. Patients are routinely counseled and advised regarding the risks of CR-BSIs and catheter care before central line insertion. Central line infections as well as bacteremia are well documented risks of chronic intravenous therapy and may significantly contribute to morbidity and mortality. Recent reports have suggested a possible increase in CR-BSI; therefore, the Scientific Leadership Council of the Pulmonary Hypertension Association decided to provide guidelines for good clinical practice regarding catheter care. Although data exits regarding patients with central venous catheters and the risk of blood stream infections in patients with cancer or other disorders, there is little data regarding the special needs of patients with pulmonary arterial hypertension requiring central venous access. These guidelines are extrapolated from the diverse body of literature regarding central venous catheter care.
Metrics
Details
- Title
- Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension
- Creators
- A. K. Doran - Pulmonary Hypertension Program, The Children's Hospital, 13123 East 19th Avenue, Aurora, CO 80045, USA.D. D. Ivy - Pulmonary Hypertension Program, The Children's Hospital, Aurora, CO, USAR. J. Barst - Columbia UniversityN. Hill - University of Alabama at BirminghamS. Murali - Division of Pulmonary, Critical Care and Sleep Medicine, Tuft's Medical Center, Boston, MA, USAR. L. Benza - Drexel UniversitySci Leadership Council Pulm Hypert
- Publication Details
- International journal of clinical practice (Esher), v 62(s160), pp 5-9
- Publisher
- Wiley
- Number of pages
- 5
- Grant note
- P50 HL084923; P50 HL084923-02 / NHLBI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) P50HL084923 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:000257773200002
- Scopus ID
- 2-s2.0-47349126435
- Other Identifier
- 991019167590904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Pharmacology & Pharmacy